In 367 adults with type 2 diabetes, the top combo dose beat 14.8% on tirzepatide alone at 48 weeks. Lilly plans phase 3 by late 2026.
Recap by typeshit. Full story at Drug Topics.
A brief Facebook post says a daily pill might help people who worry about putting weight back on once they come off Wegovy. It names no drug or study.
Alessandro Sette's lab will track T cell responses in people before and after starting GLP-1s, including to Parkinson's-linked proteins. He is enrolling himself too.
12:35
Dr. Eric Berg walks through the basics of peptides in a broad explainer. Treat any health claims as his own views.
An AI chatbot answer lays out single, dual and triple agonists, noting Lilly's retatrutide adds the glucagon receptor and is still investigational.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Loading…